Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Mehr anzeigen
Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis...
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of...
Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and...
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.9 | 16.0142348754 | 5.62 | 6.91 | 5.295 | 1213178 | 6.04525323 | CS |
| 4 | 0.61 | 10.3214890017 | 5.91 | 6.91 | 4.48 | 837758 | 5.35827656 | CS |
| 12 | -1.485 | -18.5509056839 | 8.005 | 9.1799 | 4.48 | 926370 | 6.36324371 | CS |
| 26 | -8.98 | -57.935483871 | 15.5 | 17.31 | 4.48 | 840115 | 8.98913529 | CS |
| 52 | -26.83 | -80.4497751124 | 33.35 | 36.25 | 4.48 | 847390 | 16.76729961 | CS |
| 156 | -10.08 | -60.7228915663 | 16.6 | 36.25 | 4.48 | 561751 | 17.16186263 | CS |
| 260 | -33.48 | -83.7 | 40 | 55.11 | 4.48 | 460123 | 18.66916482 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
